Novel Drug/Biologics Delivery Systems FDA Workshop Slated For July 8
This article was originally published in The Gray Sheet
FDA is soliciting feedback on regulatory challenges posed by novel drug and biologics delivery systems - and steps the agency can take to ease their regulatory pathway
You may also be interested in...
The Center for Devices & Radiological Health already is moving to implement agency-wide initiatives that seek to provide guidance for manufacturers of novel products, according to FDA officials
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.